Tahir Amin’s career began with ambitions of professional football in England before he found his calling in intellectual property law in the early 1990s.
The field was still relatively new at the time, carrying a sense of being at the frontier of legal practice that drew ambitious young lawyers seeking meaningful work.
After a decade of commercial IP practice across the UK and the United States, Amin made a decisive move to India in 2004 to see the human consequences of global patent rules firsthand.
He arrived at a pivotal moment, just as India was being required to comply with WTO patent rules that would dramatically affect access to HIV medicines costing tens of thousands of dollars annually.
Witnessing the impact of those rules on patients who could not afford treatment shaped the course of his professional life in ways commercial practice never could have.
That experience led him to co-found I-MAC in 2006, an organisation built around challenging the way intellectual property law operates in global medicine markets.
Amin has since become one of the most prominent voices examining what he describes as the political economy of drug patents and the structural advantages it grants to large pharmaceutical companies.
Central to his critique is the argument that neoliberal policy from the late 1970s onward handed control of publicly funded research to private companies, allowing them to profit from science taxpayers had already financed.
Those companies then built sprawling patent portfolios designed not primarily to reward genuine invention, but to delay the entry of cheaper generic competitors into medicine markets.
The result is a system where patents on minor reformulations or delivery changes can extend market exclusivity far beyond what the original research innovation might reasonably justify.
Amin also argues that the word “innovation” has been weaponised by the pharmaceutical industry as a rhetorical shield against scrutiny of pricing, patent practices, and market behaviour.
Whenever policymakers or campaigners raise concerns about drug affordability or patent abuse, the industry’s standard response invokes the need to protect innovation and the research investment behind it.
That framing, Amin contends, has been remarkably effective at closing down debate before the underlying questions about public interest and access are ever seriously examined.
The tension between patent protection and public health access is not new, but it has sharpened considerably as drug prices have continued to climb across both wealthy and lower-income nations.
For lawyers and policymakers engaged with these questions, Amin’s career offers a pointed example of how intellectual property expertise can be turned toward challenging the systems it once served.